The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline establishes updated clinical recommendations for the diagnosis, treatment, and management of acute coronary syndromes.
2025 ACC/AHA/ACEP/NAEMSP/SCAI clinical practice guideline for the management of acute coronary syndromes.
Absolute Event Rate: 0% vs 0%
AIM: The "2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes" incorporates new evidence since the "2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction" and the corresponding "2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes" and the "2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction." The "2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes" and the "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization" retire and replace, respectively, the "2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease." METHODS: A comprehensive literature search was conducted from July 2023 to April 2024. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.
“The DanGer Shock (Microaxial Flow Pump in Infarct-Related Cardiogenic Shock) 10-year data confirm a durable survival benefit with Impella CP (JNJ Medtech) in ST-segment elevation myocardial infarction–related cardiogenic shock (hazard ratio, 0.7; ~600 additional days alive), which is reflected in...”
Rao et al. (Thu,) reported a other. The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline establishes updated clinical recommendations for the diagnosis, treatment, and management of acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: